Alnylam Pharmaceuticals (ALNY) Stock
Commercial RNA developer with approved rare disease medicines. Here's the price, business snapshot, and what's worth knowing about Alnylam Pharmaceuticals in August 2026.
Alnylam Pharmaceuticals (ALNY) is a biotechnology company that develops RNA interference (RNAi) therapeutics to silence disease-causing genes. Investors should know it has moved from research-stage to a commercial entity, with multiple approved medicines for rare genetic disorders — including treatments for hereditary ATTR amyloidosis, acute hepatic porphyria and primary hyperoxaluria — and a broad pipeline built on its GalNAc delivery platform. The business is growth-oriented: revenues depend on uptake of marketed drugs, pricing and successful launches of late-stage candidates. Key risks include trial outcomes, regulatory decisions, pricing pressures, manufacturing scale-up and competition from other modalities. With a market capitalisation near $62.13 billion, Alnylam may appeal to investors seeking exposure to innovative therapeutics, but it suits those comfortable with biotech volatility. This is general information for educational purposes only and not personalised investment advice; values can fall as well as rise.
Why It’s Moving
ALNY is moving as investors weigh fresh conference catalysts against last month’s guidance cut
- Alnylam’s late-August attention centers on its planned ESC Congress 2026 presentation, where new clinical and real-world data could reinforce its RNAi leadership in ATTR and hypertension programs.
- The stock is still digesting last month’s weaker Q2 update and lowered 2026 revenue outlook, which reminded investors that demand in parts of the ATTR-CM market is normalizing.
- Analyst sentiment has stayed mixed but constructive, with recent rating changes and upgrades showing that the selloff has opened a debate over whether the pipeline and long-term franchise can outweigh near-term guidance pressure.
ALNY is moving as investors weigh fresh conference catalysts against last month’s guidance cut
- Alnylam’s late-August attention centers on its planned ESC Congress 2026 presentation, where new clinical and real-world data could reinforce its RNAi leadership in ATTR and hypertension programs.
- The stock is still digesting last month’s weaker Q2 update and lowered 2026 revenue outlook, which reminded investors that demand in parts of the ATTR-CM market is normalizing.
- Analyst sentiment has stayed mixed but constructive, with recent rating changes and upgrades showing that the selloff has opened a debate over whether the pipeline and long-term franchise can outweigh near-term guidance pressure.
Sixth Month Growth Performance
next-earnings-question
Alnylam Pharmaceuticals’ next earnings release is currently estimated for October 29, 2026. It will cover Q3 2026 results. This date is an estimate and may be confirmed or adjusted closer to the announcement.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Alnylam Pharmaceuticals' stock, with a target price of $329.08, indicating growth potential.
Financial Health
Alnylam Pharmaceuticals is performing well with strong profits and revenue, supported by healthy cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
RNAi platform potential
Alnylam’s GalNAc delivery platform enables targeted gene silencing across liver-related diseases, which could drive long-term growth, though clinical and commercial execution matters.
Clinical catalysts ahead
Late-stage trial readouts and new approvals can be material share-price catalysts; remember that trial or regulatory setbacks can also move the stock substantially.
Rare-disease reach
Market opportunity centres on rare, high‑need conditions where few therapies exist, but pricing, access and competition will influence commercial outcomes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
